(Q38208784)

31 August 2017

title

Galectin-3: a modifiable risk factor in heart failure (English)

1 reference

31 August 2017

0 references

0 references

5

Stefan D Anker

1 reference

31 August 2017

Dirk J van Veldhuisen

4

object named as

Dirk J van Veldhuisen

1 reference

31 August 2017

Rudolf A de Boer

1

1 reference

31 August 2017

A Rogier van der Velde

2

1 reference

31 August 2017

Christian Mueller

3

1 reference

31 August 2017

W Frank Peacock

6

1 reference

31 August 2017

Kirkwood F Adams

7

1 reference

31 August 2017

Alan Maisel

8

1 reference

31 August 2017

publication date

1 June 2014

1 reference

Cardiovascular Drugs and Therapy

31 August 2017

published in

1 reference

31 August 2017

volume

28

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

237-246

1 reference

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Epidemiology and risk profile of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

RAAS inhibitors and cardiovascular protection in large scale trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

A review of current therapies used in the treatment of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

In search of new therapeutic targets and strategies for heart failure: recent advances in basic science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth”

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Investigational drugs targeting cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 in heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3: a novel mediator of heart failure development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

The regulation of inflammation by galectin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

The immunological potential of galectin-1 and -3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3--a jack-of-all-trades in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 in cardiac remodeling and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Personalizing biomarker strategies in heart failure with galectin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Myocardial remodeling after infarction: the role of myofibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

The fibrosis marker galectin-3 and outcome in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-014-6520-2

10.1007/S10557-014-6520-2

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference